Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer - PubMed (original) (raw)
. 2006 Dec 20;24(36):5658-63.
doi: 10.1200/JCO.2006.07.0250. Epub 2006 Nov 13.
Affiliations
- PMID: 17102066
- DOI: 10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
Zsolt Gabos et al. J Clin Oncol. 2006.
Abstract
Purpose: As survival in breast cancer patients is improving, brain metastases are becoming increasingly prevalent. The risk of brain metastases in newly diagnosed human epidermal growth factor receptor 2 (HER-2) -overexpressing breast cancer patients is not yet fully defined. We aimed to analyze the risk of brain metastasis in newly diagnosed HER-2-positive breast cancer patients in comparison with HER-2-negative patients.
Patients and methods: To determine the incidence of brain metastases in HER-2-overexpressing patients, we analyzed a cohort of newly diagnosed 301 HER-2-positive and 363 HER-2-negative patients identified between January 1998 and December 2003. The association between histologic features and the occurrence of brain metastases was evaluated with univariate and multivariate Cox regression analysis.
Results: Median follow-up was 3.9 years. Brain metastases were identified in 9% (27 patients) with HER-2-overexpressing breast cancer compared with only 1.9% (7 patients) in the HER-2 negative patients (hazard ratio 4.23 [1.84-9.74], P = .0007). HER-2 overexpression, tumor size larger than 2 cm, at least one positive node, and grade 2/3 disease were predictors of brain metastases in univariate analysis. In multivariate analysis, HER-2 overexpression, tumor size larger than 2 cm, and hormone-receptor negativity were independent prognostic factors for the development of brain metastases, whereas hormone-receptor expression was protective.
Conclusion: Our study shows that newly diagnosed HER-2-overexpressing breast cancer patients are at increased risk for brain metastases. Because most brain metastases occur after the development of systemic disease, these findings prompt consideration of brain prophylaxis strategies with HER-2-inhibiting small molecules able to cross the blood-brain barrier and/or radiologic screening to detect asymptomatic brain metastases.
Comment in
- Is prophylactic cranial irradiation a possible option for human epidermal growth factor receptor 2-positive breast cancer?
Buyukhatipoglu H, Sevinc A, Pehlivan Y, Camci C. Buyukhatipoglu H, et al. J Clin Oncol. 2007 Apr 1;25(10):1292; author reply 1293. doi: 10.1200/JCO.2006.10.1253. J Clin Oncol. 2007. PMID: 17401024 No abstract available.
Similar articles
- Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Tham YL, et al. Cancer. 2006 Aug 15;107(4):696-704. doi: 10.1002/cncr.22041. Cancer. 2006. PMID: 16826579 - Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Eichler AF, et al. Cancer. 2008 Jun;112(11):2359-67. doi: 10.1002/cncr.23468. Cancer. 2008. PMID: 18361426 Clinical Trial. - Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P. Bartlett JM, et al. J Clin Oncol. 2007 Oct 1;25(28):4423-30. doi: 10.1200/JCO.2007.11.0973. J Clin Oncol. 2007. PMID: 17906205 - Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge.
Stemmler HJ, Heinemann V. Stemmler HJ, et al. Oncologist. 2008 Jul;13(7):739-50. doi: 10.1634/theoncologist.2008-0052. Epub 2008 Jul 9. Oncologist. 2008. PMID: 18614587 Review. - Breast cancer brain metastases.
Cheng X, Hung MC. Cheng X, et al. Cancer Metastasis Rev. 2007 Dec;26(3-4):635-43. doi: 10.1007/s10555-007-9083-x. Cancer Metastasis Rev. 2007. PMID: 17717635 Review.
Cited by
- Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases.
Zhang Q, Yan X, Tian TL, Wu X. Zhang Q, et al. Front Pharmacol. 2024 Aug 19;15:1381478. doi: 10.3389/fphar.2024.1381478. eCollection 2024. Front Pharmacol. 2024. PMID: 39224773 Free PMC article. - CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.
Wang T, Chen J, Yang J, Fu M, Hua W, Jia W, Liu Y, Wang B, Yan M, Zhou J, Hao C, Chen J, Ou D, Jiang T, Mao Y, Jiang Z; CSCO expert panel of breast cancer*; CSCO expert panel of breast cancer. Wang T, et al. Transl Breast Cancer Res. 2022 Jul 30;3:22. doi: 10.21037/tbcr-22-30. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751521 Free PMC article. Review. - The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis.
Poletes C, Amanirad B, Santiago AT, Yan M, Conrad T, Jerzak KJ, Shultz DB. Poletes C, et al. J Neurooncol. 2024 Aug;169(1):119-127. doi: 10.1007/s11060-024-04707-1. Epub 2024 May 13. J Neurooncol. 2024. PMID: 38740672 - Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.
Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, Ergle A. Rubin E, et al. Int J Mol Sci. 2024 Jan 15;25(2):1064. doi: 10.3390/ijms25021064. Int J Mol Sci. 2024. PMID: 38256137 Free PMC article. Review. - Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.
Liang K, Feliciano JL, Marrone KA, Murray JC, Hann CL, Anagnostou V, Tackett SA, Shin EJ, Hales RK, Voong KR, Battafarano RJ, Yang SC, Broderick SR, Ha JS, Forde PM, Brahmer JR, Lam VK. Liang K, et al. ESMO Open. 2024 Jan;9(1):102199. doi: 10.1016/j.esmoop.2023.102199. Epub 2023 Dec 9. ESMO Open. 2024. PMID: 38071928 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous